
Rewriting the rules of genetic medicine with tRNA therapeutics
Episode 214
Most genetic medicines are built to treat one gene, one mutation, one disease at a time. That's true even for the newest modalities — gene therapy, gene editing, mRNA — each still has to be engineered disease by disease. Alltrna is testing a different idea: that the real target isn't the gene, but the process of translation itself, where genetic instructions become protein. The company's lead approach focuses on nonsense mutations, a shared error responsible for roughly a tenth of all genetic disease diagnoses, and asks whether a single engineered molecule could address it across many conditions at once. My guest today is Dr. Nerissa Kreher, Chief Medical Officer of Alltrna. Nerissa brings two decades of rare disease drug development experience, including CMO roles at Entrada Therapeutics, Tiburio Therapeutics, and AVROBIO, to the task of turning that platform thesis into an actual clinical program. We'll talk translation, trial design, and what it takes to bring the first engineered tRNA therapy into the clinic. 02:45 Meet Nerissa Kreher and Alltrna's tRNA platform 07:29 Gene-by-gene versus mutation-by-mutation drug development 12:08 What nonsense mutations are and why they matter 15:55 Phase 1 trial approval in Australia 19:49 What basket trials are and FDA receptiveness 27:27 Where Alltrna could be in five years Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Publisher
Beyond Biotech - the podcast from Labiotech
Published
September 11, 2026
Duration
31 min
Format
Podcast
Category
Issues · Tech News
Source
RSS feed
Host
Labiotech
Beyond Biotech - the podcast from Labiotech
@beyondbiotechthepodcastfroml
#rewriting #geneticmedicine #trnatherapeutics
